Single-factor analyses of time-varying factors for progression of clinical damage
| Factor | Single-factor analyses | All factors included | ||
|---|---|---|---|---|
| Relative damage rate (95% CI) | p Value | Relative damage rate (95% CI) | p Value | |
| DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug. | ||||
| Functional class | <0.001 | 0.1 | ||
| Good (I) | 1 | 1 | ||
| Medium (II) | 1.56 (1.24 to 1.96) | 1.16 (0.89 to 1.5) | ||
| Poor (III, IV) | 1.37 (0.96 to 1.91) | 0.87 (0.59 to 1.28) | ||
| Tender joints | <0.001 | 0.2 | ||
| None (0) | 1 | 1 | ||
| Low (1–4) | 1.45 (1.13 to 1.86) | 1.15 (0.89 to 1.51) | ||
| Medium (5–9) | 1.63 (1.19 to 2.24) | 1.27 (0.91 to 1.78) | ||
| High (>9) | 2.09 (1.54 to 2.85) | 1.37 (0.97 to 1.95) | ||
| Effusions | <0.001 | <0.001 | ||
| None (0) | 1 | 1 | ||
| Low (1–4) | 1.32 (1.07 to 1.63) | 1.12 (0.89 to 1.42) | ||
| Medium (5–9) | 1.84 (1.33 to 2.55) | 1.48 (1.02 to 2.13) | ||
| High (>9) | 2.95 (1.82 to 4.78) | 2.6 (1.56 to 4.36) | ||
| ESR | 0.17 | 0.75 | ||
| Low (<15) | 1 | 1 | ||
| Medium (15–30) | 1.05 (0.82 to 1.39) | 0.99 (0.77 to 1.28) | ||
| High (>30) | 1.27 (0.94 to 1.73) | 1.09 (0.8 to 1.48) | ||
| Arthritis duration | 0.67 (0.55 to 0.8) per extra decade in clinic | <0.001 | 0.73 (0.6 to 0.89) | <0.001 |
| Drugs | 0.143 | 0.044 | ||
| None | 1 | 1 | ||
| NSAIDs | 0.72 (0.44 to 1.18) | 1.11 (0.65 to 1.91) | ||
| DMARDs | 0.89 (0.6 to 1.32) | 1.32 (0.84 to 2.07) | ||
| Steroids | 1.04 (0.68 to 1.6) | 1.64 (1.02 to 2.68) | ||